Having money tied up in an overhyped spec company whilst missing...

Having money tied up in an overhyped spec company whilst missing out on serious profits from companies like AVB, CCC, RDS, BML and so on in 2010 is frustrating for any shareholder..

A larger degree of patience is required for the biotechs which don't have a tangible asset in the ground however patience and optimism do have limits.. I'm disappointed to sell off half my holdings too de-risk but 2010 is looking very much like a flop for Stirling IMO.

We were promised much more by management and it's now mid November... Do they have any credibility..? Not so sure..

My thoughts,

Oracle72